Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of Droxidopa for the treatment of
fatigue in patients with Parkinsonism by the Visual Analog Fatigue Scale (VAFS). This is a
randomized, placebo-controlled, double-blind clinical trial for 3 months where half the
subjects will receive placebo and the other half will receive Droxidopa. Following this will
be a wash-out period of 7 days and then all subjects will receive Droxidopa for 3 months
during the open-label phase.